Detalhe da pesquisa
1.
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
N Engl J Med
; 390(15): 1394-1407, 2024 04 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38587233
2.
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
N Engl J Med
; 389(12): 1069-1084, 2023 Sep 21.
Artigo
Inglês
| MEDLINE | ID: mdl-37622681
3.
Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
Circulation
; 149(11): 825-838, 2024 03 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38059368
4.
Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
Circulation
; 149(3): 204-216, 2024 01 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37952180
5.
Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort Analysis.
Circulation
; 149(4): 293-304, 2024 01 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37950893
6.
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Lancet
; 403(10437): 1635-1648, 2024 Apr 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38599221
7.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
N Engl J Med
; 387(12): 1089-1098, 2022 09 22.
Artigo
Inglês
| MEDLINE | ID: mdl-36027570
8.
Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
Eur Heart J
; 2024 May 13.
Artigo
Inglês
| MEDLINE | ID: mdl-38739118
9.
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Annu Rev Physiol
; 83: 503-528, 2021 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33197224
10.
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
Circulation
; 147(4): 284-295, 2023 Jan 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36335517
11.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
N Engl J Med
; 384(2): 117-128, 2021 01 14.
Artigo
Inglês
| MEDLINE | ID: mdl-33200892
12.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
N Engl J Med
; 385(16): 1451-1461, 2021 10 14.
Artigo
Inglês
| MEDLINE | ID: mdl-34449189
13.
GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage.
Am J Physiol Heart Circ Physiol
; 326(5): H1159-H1176, 2024 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38426865
14.
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease.
Am J Physiol Heart Circ Physiol
; 326(3): H670-H688, 2024 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38133623
15.
Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions.
Curr Cardiol Rep
; 26(3): 61-71, 2024 03.
Artigo
Inglês
| MEDLINE | ID: mdl-38551786
16.
The cardiovascular effects of novel weight loss therapies.
Eur Heart J
; 44(48): 5036-5048, 2023 Dec 21.
Artigo
Inglês
| MEDLINE | ID: mdl-37966486
17.
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction.
Eur Heart J
; 44(37): 3640-3651, 2023 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37674356
18.
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table.
Eur Heart J
; 44(39): 4141-4156, 2023 Oct 14.
Artigo
Inglês
| MEDLINE | ID: mdl-37448181
19.
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
Circulation
; 146(24): 1882-1894, 2022 12 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36508493
20.
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Circulation
; 145(3): 184-193, 2022 01 18.
Artigo
Inglês
| MEDLINE | ID: mdl-34779658